Tag: Lysogene
Lysogene announces the conversion of the receivership proceedings into judicial liquidation and its delisting
HC Published on 05/26/2023 at 6:29 p.m. (Boursier.com) — Lysogen a phase 3 biopharmaceutical company…
Lysogene: placed in liquidation and delisted
(CercleFinance.com) – The biopharmaceutical company Lysogene, which has been in financial difficulty for several months, has announced that it has been placed in compulsory liquidation proceedings by the Commercial Court…
Lysogene: placed in liquidation and delisted – 05/29/2023 at 11:17
(CercleFinance.com) – The biopharmaceutical company Lysogene, which has been in financial difficulty for several months, has announced that it has been placed in compulsory liquidation proceedings by the Commercial Court…
Lysogene: End of the game for Lysogene, whose action will be delisted after its liquidation
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Lysogene: no takeover offer filed – 2023-04-14 at 18:12
(AOF) – Lysogene announces that no takeover offer has been filed before the filing deadline set for April 12, 2023, despite two successive postponements. As a reminder, the search procedure…
Lysogene: further postponement of the date of submission of takeover offers
AS Published on 03/27/2023 at 07:04 (Boursier.com) — Lysogen again postpones the deadline…
Lysogene: the interim CFO is confirmed – 02/06/2023 at 16:22
(CercleFinance.com) – Lysogene, a biopharmaceutical company specializing in gene therapies, announced on Monday the appointment of Côme de La Tour du Pin as Chief Financial Officer. The senior executive had…
Lysogene: appointment of Côme de La Tour du Pin
By Hector Chaunu Published on 02/03/2023 at 6:25 p.m. (Boursier.com) — Lysogen , a Phase…
Lysogene: Côme de La Tour du Pin appointed Chief Financial Officer – 02/03/2023 at 18:12
(AOF) – Lysogene, a biopharmaceutical company based on a gene therapy technology platform targeting diseases of the central nervous system, today announces the appointment of Côme de La Tour du…
Lysogene: the company placed in receivership – 01/25/2023 at 11:50 am
(CercleFinance.com) – The biopharmaceutical company Lysogene announced on Wednesday that it had been placed in receivership by the Commercial Court of Nanterre. The gene therapy company, which specializes in diseases…
Lysogene: officially looking for a buyer – 01/09/2023 at 11:36
(CercleFinance.com) – Lysogene announced on Friday that it was looking for a buyer or an investor with the formalization of the opening of receivership proceedings. The biopharmaceutical company, specializing in…
Lysogene requests receivership and is looking for buyers – 01/06/2023 at 18:09
(AOF) – Lysogene, a biopharmaceutical company specializing in gene therapy targeting diseases of the central nervous system, announces that it has requested, jointly with the receiver, the conversion of the…